These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 12376040)

  • 1. Gatifloxacin in community-based treatment of acute respiratory tract infections in the elderly.
    Nicholson SC; High KP; Gothelf S; Webb CD
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):109-16. PubMed ID: 12376040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of gatifloxacin in elderly outpatients with community-acquired pneumonia.
    Nicholson SC; Wilson WR; Naughton BJ; Gothelf S; Webb CD
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):117-25. PubMed ID: 12376041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral gatifloxacin in outpatient community-acquired pneumonia: results from TeqCES, a community-based, open-label, multicenter study.
    Gotfried M; Quinn TC; Gothelf S; Wikler MA; Webb CD; Nicholson SC
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):85-91. PubMed ID: 12376037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter evaluation of the efficacy and safety of gatifloxacin in Mexican adult outpatients with respiratory tract infections.
    Casillas JL; Rico G; Rodríguez-Parga D; Mascareño A; Rangel-Frausto S
    Adv Ther; 2000; 17(6):263-71. PubMed ID: 11317829
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemophilus influenzae in respiratory tract infections in community-based clinical practice: therapy with gatifloxacin.
    Nicholson SC; Webb CD; Andriole VT; Jones RN; Wilson WR
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):101-7. PubMed ID: 12376039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implications of TeqCES: efficacy and safety of gatifloxacin in community-acquired pneumonia.
    Mandell LA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):127-8. PubMed ID: 12376042
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of adults with community-acquired respiratory tract infections: results of a multicentric clinical trial with gatifloxacin.
    Medeiros EA
    Braz J Infect Dis; 2002 Aug; 6(4):149-56. PubMed ID: 12204181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Community-based treatment of acute uncomplicated bacterial rhinosinusitis with gatifloxacin.
    Sher LD; Poole MD; Von Seggern K; Wikler MA; Nicholson SC; Pankey GA
    Otolaryngol Head Neck Surg; 2002 Sep; 127(3):182-9. PubMed ID: 12297808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
    Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY
    Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
    Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae.
    Jones RN; Andes DR; Mandell LA; Gothelf S; Ehrhardt AF; Nicholson SC
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):93-100. PubMed ID: 12376038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open label, multicenter, non-comparative study of the efficacy and safety of oral gatifloxacin in the treatment of community-acquired pneumonia: a Brazilian study in five centers.
    Nicodemo AC
    Braz J Infect Dis; 2003 Feb; 7(1):62-8. PubMed ID: 12807692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of gatifloxacin in community-acquired pneumonia: rationale for the Tequin Clinical Experience Study (TeqCES).
    Mandell LA
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):65-7. PubMed ID: 12376034
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of gemifloxacin 320 mg once-daily for 7 days in the treatment of adult lower respiratory tract infections.
    Ball P; File TM; Twynholm M; Henkel T
    Int J Antimicrob Agents; 2001 Jul; 18(1):19-27. PubMed ID: 11463522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gatifloxacin in community-acquired respiratory tract infection.
    Sethi S
    Expert Opin Pharmacother; 2003 Oct; 4(10):1847-55. PubMed ID: 14521494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gatifloxacin: a review of its use in the management of bacterial infections.
    Perry CM; Ormrod D; Hurst M; Onrust SV
    Drugs; 2002; 62(1):169-207. PubMed ID: 11790160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 5-day, short-course gatifloxacin therapy with 7-day gatifloxacin therapy and 10-day clarithromycin therapy for acute exacerbation of chronic bronchitis.
    Gotfried MH; DeAbate CA; Fogarty C; Mathew CP; Sokol WN
    Clin Ther; 2001 Jan; 23(1):97-107. PubMed ID: 11219483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness, safety and tolerability of gatifloxacin, a new 8-methoxyfluoroquinolone, in the treatment of outpatients with community-acquired pneumonia: a Brazilian study.
    Franca SA; Carvalho CR
    Braz J Infect Dis; 2002 Aug; 6(4):157-63. PubMed ID: 12204182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of gatifloxacin in community treatment of acute exacerbations of chronic bronchitis.
    Anzueto A; Gotfried M; Wikler MA; Russo R; Nicholson SC
    Clin Ther; 2002 Jun; 24(6):906-17. PubMed ID: 12117081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of levofloxacin in the treatment of lower respiratory tract infections (LRTIs).
    Blasi F
    J Chemother; 2004 Apr; 16 Suppl 2():11-4. PubMed ID: 15255556
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.